Eurofins bioskin GmbH
- Address
- lock Available on a paid plan
Skin and Connective Tissue Diseases Research
At Eurofins bioskin GmbH in Hamburg, the clinical trial portfolio focuses on skin and connective tissue diseases, with studies centered on conditions that affect both appearance and quality of life. The research is aimed at evaluating new treatment options and understanding how well they work for common dermatologic disorders.
- Androgenetic alopecia, with trials assessing whether a new therapy can improve male pattern hair loss
- Psoriasis vulgaris, studied to better understand treatment safety and effectiveness
- Psoriatic arthritis, included in research exploring therapies that may address both skin and joint symptoms
This site supports clinical research that combines dermatology and broader inflammatory disease care, helping to test potential treatments for patients with chronic skin-related conditions.
Dermatology and Inflammatory Disease Studies
The clinical trials at this Hamburg research site are concentrated on diseases of the skin, with a strong emphasis on evaluating the safety and effectiveness of emerging therapies. The work includes studies designed to improve care for hair loss and inflammatory conditions that can significantly affect daily life.
- Male pattern hair loss, with research focused on testing a new topical treatment approach
- Psoriasis vulgaris, examined in studies of treatment tolerability and symptom control
- Psoriatic arthritis, included to explore therapies for a condition linking skin inflammation and joint involvement
Overall, the site contributes to clinical development in inflammatory skin disease and related disorders, with trials aimed at generating evidence for future treatment options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Novartis Pharma AG2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Eurofins bioskin GmbH
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicenter, randomized, participant- and investigator -blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitis | Novartis Pharma AG | Phase II | Not Yet Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amlitelimab | 5 | Unknown | 2022-11-10 | 2024-10-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.